betamethasone-17,21-dipropionate and halobetasol

betamethasone-17,21-dipropionate has been researched along with halobetasol in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (37.50)	18.2507
2000's	3 (37.50)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (25.00)	2.80

Authors

Authors	Studies
Korsukewitz, G; Mensing, H; Yawalkar, S	1
Schwerzmann, L; Yawalkar, SJ	1
Aeling, JL; Huff, L; Walsh, P; Weston, WL	1
Hecker, D; Lebwohl, M; Worsley, J; Yueh, G	1
Frieden, IJ; Garzon, MC; Hawrot, A; Lucky, AW	1
Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ	1
Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1

Reviews

1 review(s) available for betamethasone-17,21-dipropionate and halobetasol

Article	Year
Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:2 Topics: Administration, Cutaneous; Betamethasone; Clobetasol; Extremities; Eye Neoplasms; Eyelids; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2005

Trials

3 trial(s) available for betamethasone-17,21-dipropionate and halobetasol

Article	Year
A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. Journal of the American Academy of Dermatology, 1991, Volume: 25, Issue:6 Pt 2 Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Chronic Disease; Clobetasol; Double-Blind Method; Female; Germany; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Psoriasis; Remission Induction; Vasoconstrictor Agents; Wound Healing	1991
Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. Journal of the American Academy of Dermatology, 1991, Volume: 25, Issue:6 Pt 2 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Clobetasol; Dermatitis, Atopic; Double-Blind Method; Female; Germany, West; Glucocorticoids; Humans; Male; Middle Aged; Patient Satisfaction; Remission Induction; Vasoconstrictor Agents	1991
Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. Journal of the American Academy of Dermatology, 1993, Volume: 29, Issue:3 Topics: Betamethasone; Clobetasol; Double-Blind Method; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Pituitary-Adrenal System; Psoriasis	1993

Other Studies

4 other study(ies) available for betamethasone-17,21-dipropionate and halobetasol

Article	Year
In vitro compatibility of tazarotene with other topical treatments of psoriasis. Journal of the American Academy of Dermatology, 2000, Volume: 42, Issue:6 Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis	2000
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi Journal of medical economics, 2020, Volume: 23, Issue:12 Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis	2020
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju Journal of medical economics, 2020, Volume: 23, Issue:12 Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis	2020
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004